WO2003074565A3 - Peptides utilisables en immunotherapie antitumorale. - Google Patents

Peptides utilisables en immunotherapie antitumorale. Download PDF

Info

Publication number
WO2003074565A3
WO2003074565A3 PCT/FR2003/000698 FR0300698W WO03074565A3 WO 2003074565 A3 WO2003074565 A3 WO 2003074565A3 FR 0300698 W FR0300698 W FR 0300698W WO 03074565 A3 WO03074565 A3 WO 03074565A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
antitumor immunotherapy
immunotherapy
antitumor
melan
Prior art date
Application number
PCT/FR2003/000698
Other languages
English (en)
Other versions
WO2003074565A2 (fr
Inventor
Boris Linard
Francine Jotereau
Houssem Benlalam
Elizabeth Diez
Yannick Guilloux
Nathalie Labarriere
Nadine Gervois
Laurent Derre
Original Assignee
Inst Nat Sante Rech Med
Univ Nantes
Boris Linard
Francine Jotereau
Houssem Benlalam
Elizabeth Diez
Yannick Guilloux
Nathalie Labarriere
Nadine Gervois
Laurent Derre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Nantes, Boris Linard, Francine Jotereau, Houssem Benlalam, Elizabeth Diez, Yannick Guilloux, Nathalie Labarriere, Nadine Gervois, Laurent Derre filed Critical Inst Nat Sante Rech Med
Priority to EP03743400A priority Critical patent/EP1481009A2/fr
Priority to AU2003232280A priority patent/AU2003232280A1/en
Priority to JP2003573030A priority patent/JP2005533487A/ja
Priority to US10/506,334 priority patent/US20060122119A1/en
Priority to CA002477762A priority patent/CA2477762A1/fr
Publication of WO2003074565A2 publication Critical patent/WO2003074565A2/fr
Publication of WO2003074565A3 publication Critical patent/WO2003074565A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

L'invention concerne l'utilisation de peptides immunogènes représentant des épitopes T présentés par le CMH I, dérivés des antigènes Melan-A, MAGE-A6, gp100, tyrosinase et NY-ESO-1 dans le cadre du diagnostic ou du traitement des mélanomes chez des sujets HLA-B35.
PCT/FR2003/000698 2002-03-04 2003-03-04 Peptides utilisables en immunotherapie antitumorale. WO2003074565A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03743400A EP1481009A2 (fr) 2002-03-04 2003-03-04 Peptides utilisables en immunotherapie antitumorale.
AU2003232280A AU2003232280A1 (en) 2002-03-04 2003-03-04 Peptides for use in antitumor immunotherapy
JP2003573030A JP2005533487A (ja) 2002-03-04 2003-03-04 抗腫瘍免疫療法における使用のためのペプチド
US10/506,334 US20060122119A1 (en) 2002-03-04 2003-03-04 Peptides for use in antitumor immunotherapy
CA002477762A CA2477762A1 (fr) 2002-03-04 2003-03-04 Peptides utilisables en immunotherapie antitumorale

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0202703A FR2836684B1 (fr) 2002-03-04 2002-03-04 Peptides ras mutes et leur utilisation en immunotherapie
FR02/02703 2002-03-04

Publications (2)

Publication Number Publication Date
WO2003074565A2 WO2003074565A2 (fr) 2003-09-12
WO2003074565A3 true WO2003074565A3 (fr) 2004-07-08

Family

ID=27741417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000698 WO2003074565A2 (fr) 2002-03-04 2003-03-04 Peptides utilisables en immunotherapie antitumorale.

Country Status (7)

Country Link
US (1) US20060122119A1 (fr)
EP (1) EP1481009A2 (fr)
JP (1) JP2005533487A (fr)
AU (1) AU2003232280A1 (fr)
CA (1) CA2477762A1 (fr)
FR (1) FR2836684B1 (fr)
WO (1) WO2003074565A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221060A1 (fr) * 2009-02-05 2010-08-25 Universitätsklinikum Heidelberg Utilisation de peptides spécifiques pour la préparation d'un médicament pour le traitement d'hyperglobulinémie monoclonale de signification indéterminée ou de myélome multiple couvant
EP3604271A1 (fr) * 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides pour conjugués d'acide aminé et de peptides et procédé de conjugaison
CN112739375A (zh) * 2018-08-17 2021-04-30 磨石肿瘤生物技术公司 靶向共同抗原的抗原结合蛋白
IL266728B (en) * 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021551A1 (fr) * 1998-10-09 2000-04-20 Ludwig Institute For Cancer Research Peptides isoles se fixant aux molecules hla-b35
WO2001016320A1 (fr) * 1999-08-30 2001-03-08 Ludwig Institute For Cancer Research Nonapeptides et decapeptides se fixant aux molecules hla et utilisation
WO2001053833A1 (fr) * 2000-01-20 2001-07-26 Ludwig Institute For Cancer Research Peptides antigeniques mage fixant hla-b35 and hla-b44
WO2001090197A1 (fr) * 2000-05-26 2001-11-29 The Australian National University Peptides synthetiques et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021551A1 (fr) * 1998-10-09 2000-04-20 Ludwig Institute For Cancer Research Peptides isoles se fixant aux molecules hla-b35
WO2001016320A1 (fr) * 1999-08-30 2001-03-08 Ludwig Institute For Cancer Research Nonapeptides et decapeptides se fixant aux molecules hla et utilisation
WO2001053833A1 (fr) * 2000-01-20 2001-07-26 Ludwig Institute For Cancer Research Peptides antigeniques mage fixant hla-b35 and hla-b44
WO2001090197A1 (fr) * 2000-05-26 2001-11-29 The Australian National University Peptides synthetiques et leurs utilisations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENLALAM H ET AL: "Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.", EUROPEAN JOURNAL OF IMMUNOLOGY. GERMANY JUL 2001, vol. 31, no. 7, July 2001 (2001-07-01), pages 2007 - 2015, XP002265727, ISSN: 0014-2980 *
MENDEZ R ET AL: "Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy.", TISSUE ANTIGENS. DENMARK JUN 2001, vol. 57, no. 6, June 2001 (2001-06-01), pages 508 - 519, XP002265728, ISSN: 0001-2815 *
ROMERO P ET AL: "Therapeutic cancer vaccines based on molecularly defined human tumor antigens", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, 19 December 2002 (2002-12-19), pages A2 - A7, XP004397465, ISSN: 0264-410X *
VALMORI D ET AL: "DIVERSITY OF THE FINE SPECIFICITY DISPLAYED BY HLA-A*0201-RESTRICTED CTL SPECIFIC FOR THE IMMUNODOMINANT MELAN-A/MART-1 ANTIGENIC PEPTIDE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 161, no. 12, 1998, pages 6956 - 6962, XP000886281, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2003232280A1 (en) 2003-09-16
EP1481009A2 (fr) 2004-12-01
CA2477762A1 (fr) 2003-09-12
US20060122119A1 (en) 2006-06-08
FR2836684A1 (fr) 2003-09-05
JP2005533487A (ja) 2005-11-10
AU2003232280A8 (en) 2003-09-16
FR2836684B1 (fr) 2004-12-17
WO2003074565A2 (fr) 2003-09-12

Similar Documents

Publication Publication Date Title
EP2359841A3 (fr) Peptides dérivés de la survivine et leurs utilisations
EP2388271A3 (fr) Proteines et Anticorps Humains
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
EP2562183A8 (fr) Nouveaux épitopes immunogènes pour lýimmunothérapie
EP2316486A3 (fr) Anticorps à cripto-blocage et utilisations correspondantes
WO2006081007A3 (fr) Utilisation de flagelline en immunotherapie antitumorale
EP2338506A3 (fr) Combinaisons d'antigènes associés aux tumeurs pour le traitement thérapeutique de différents types de cancer
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2006119527A3 (fr) Diagnostic du melanome
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2002026819A3 (fr) Vaccins b.c.g. de recombinaison aux fins du traitement et de la prevention du cancer
PL371278A1 (en) Modified factor viii
IL145926A0 (en) Peptide epitopes of mimotopes useful in immunomodulation
AU2003267401A1 (en) Novel mhc ii associated peptides
EP1660686A4 (fr) Epitopes des lymphocytes t hpv cd8+
WO2003074565A3 (fr) Peptides utilisables en immunotherapie antitumorale.
EP2277918A3 (fr) Antigène peptide mhc classe I et II dérivé d'une tumeur antigène 5t4
EP2193804A3 (fr) Toxine d'adénylate-cyclase récombinante de Bordetella induisant des réponses des lymphocytes T contre des antigènes tumoraux
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
WO2001029220A3 (fr) Peptides antigeniques mage-a12 et utilisation
WO2004105681A3 (fr) Epitopes du papillomavirus humain (hpv) cd4+
WO2000055194A3 (fr) Antigenes de la tuberculose et procedes de leur utilisation
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
EP1370697A4 (fr) Medicaments a base de peroxyredoxine pour le traitement d'infections par le vih-1, et leurs methodes d'utilisation
WO2002070679A3 (fr) Vaccins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2477762

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003573030

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003743400

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003743400

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006122119

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10506334

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10506334

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003743400

Country of ref document: EP